Birkett Bernard 4
4 · WEST PHARMACEUTICAL SERVICES INC · Filed Aug 8, 2023
Insider Transaction Report
Form 4
Birkett Bernard
Sr VP, Chief Financial Officer
Transactions
- Sale
Common Stock
2023-08-02$371.02/sh−200$74,205→ 4,366 total - Sale
Common Stock
2023-08-02$370.38/sh−22,134$8,198,011→ 4,566 total - Exercise/Conversion
Common Stock
2023-08-02$102.51/sh+8,450$866,210→ 12,816 total - Exercise/Conversion
Stock Options (Right to buy)
2023-08-02−8,450→ 6,850 totalExercise: $102.51From: 2020-02-19Exp: 2029-02-19→ Common Stock (8,450 underlying) - Exercise/Conversion
Common Stock
2023-08-02$100.92/sh+13,884$1,401,173→ 26,700 total - Exercise/Conversion
Stock Options (Right to buy)
2023-08-02−13,884→ 0 totalExercise: $100.92From: 2019-06-21Exp: 2028-06-21→ Common Stock (13,884 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $370.00 to $370.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- [F2]The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $371.00 to $371.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- [F3]This award vests in four equal annual installments beginning on February 19, 2020.
- [F4]This award vests over four years starting on the first anniversary date of the award.